Obesity Market Strategy

Positioning Obesity Therapies for Success

Coverage, Adoption, Growth & Innovation:
A Smarter Strategy for Obesity Drugs

The obesity pharmaceutical market is booming, fueled by rising obesity rates, increased recognition as a chronic disease, and breakthrough GLP-1 therapies. However, maximizing GLP-1 market access requires innovative and strategic access models to navigate a highly competitive therapeutic landscape, shifting provider and patient preferences, and a payer environment that continues to restrict coverage—often treating weight loss as a lifestyle choice rather than a medical necessity.

At The Dedham Group, we help pharma manufacturers overcome market access barriers and maximize commercial success. Through in-depth assessments across all key access levers, we develop integrated strategies to streamline launch, indication expansion, and lifecycle management. Our expertise in strategic access innovation, stakeholder channel optimization (e.g., provider & payer channels), and competitive positioning enhancement ensures obesity treatments are positioned as essential chronic disease therapies—driving greater access through both traditional and non-traditional access channels, adoption, and long-term commercial success.

Schedule a Meeting

Learn more about the Dedham Group’s Strategy Expertise:

Our Tailored Services for Success:

Value & Access Strategy

Payer & Employer Strategy:
Develop engagement strategies to mitigate or complement future AOM coverage dynamics & identify emerging market shifts to identify mitigation strategies and / or identify value enhancing opportunities

Emerging Alternative PBM Model Deep-Dive:
Identify and analyze emerging alternative Pharmacy Benefit Manager models to understand their impact on drug access and reimbursement

Point Solution Landscape Assessment:
Evaluate emerging digital obesity solutions (e.g., Omada, Livongo, Noom, Virta, etc.) that can enhance or restrict patient access to obesity treatments

Provider Channel Pull-Through

Provider Account Prioritization & Engagement:
Identify and engage key healthcare providers / accounts (e.g., IDN, Health Systems, Community Practices) to drive favorable value perceptions & ultimately optimize engagement strategies to enhance therapy adoption

Alternative Site of Care Opportunities:
Explore emerging non-traditional care settings, such as urgent care, medical spas or telehealth, for prescribing and administering obesity treatments

Direct-to-Patient:
Implement strategies to engage patients directly (e.g., Direct-To-Consumer channel activation via telehealth + digital pharmacy integration, AI-tethered patient identification), increasing their awareness, education and access to obesity treatments

3rd Party Stakeholder Activation

DTC Channel Strategy:
Develop direct-to-consumer strategies to streamline therapy access & enhance AOM brand value perceptions

Emerging Access Solution Ideation:
Innovate new solutions (e.g., AI-integrated precision medicine, EMR Data Mining technology, combination prescription & companion digital therapeutics) to directly address key access journey patient points & emerging market challenges

Innovative Solution Execution & key Implementation:
Develop key 3^rd party solution benchmarking and comprehensive roadmap / playbook for innovative access solution strategy execution to improve obesity therapy value perceptions

We Provide:

Dedicated Stakeholder Panel

The Dedham Group manages all U.S. panel relationships and utilizes a mix of owned and vendor-supported relationships for ex-U.S. markets.

Integrated
Norstella Data

Our combined data set enhances capabilities and strengthens resourcing for Dedham’s strategic projects.

Specialized Chronic Disease Division

Over 20 years of experience in complex and innovative healthcare categories, with specialized expertise in chronic care.

Additional Resource

Four Strategies for Competing in the Crowded Obesity Drug Marketplace

Over 100 million Americans are classified as medically overweight, making obesity one of the fastest growing public health issues in the U.S. The anti-obesity medication (AOM) marketplace is rapidly expanding, fueled by the increasing demand for effective weight management and metabolic health solutions. With potential Medicare coverage on the horizon and increasing patient demand, the obesity space promises to grow at an unprecedented rate.